Why Smaller Companies Funds Have Outperformed

The average UK smaller companies fund has comfortably outperformed the FTSE Small Cap and Numis Smaller Companies indices in 2017 so far

Samuel Meakin 18 October, 2017 | 12:34PM
Facebook Twitter LinkedIn

The average UK smaller companies fund has comfortably outperformed the FTSE Small Cap and Numis Smaller Companies indices in 2017 so far, with the average fund returning 20.6% versus 12.6% for the FTSE and 14.9% for the Numis. Why is this?

There has certainly been a stylistic tailwind benefitting active funds in the period. The category average demonstrates a clear growth bias relative to the FTSE Small Cap index, and small-cap growth stocks as defined by Morningstar have outperformed small-cap value stocks in 2017 to the end of September. Nonetheless, the average fund has also been able to demonstrate strong stock selection on top of that to help drive home the gains over the index over this period.

When compared to the Numis index rather than the FTSE, the category average’s growth bias still remains, but it is less pronounced. The stylistic tailwind versus this index has thus been smaller, but attribution analysis again shows that strong stock selection has helped the average fund to outperform.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Clinigen Group PLC628.00 GBX-2.94
Dechra Pharmaceuticals PLC5,145.00 GBX-1.53
FDM Group (Holdings) PLC1,210.00 GBX-0.66
Fevertree Drinks PLC2,299.00 GBX-3.44
Foxtons Group PLC48.00 GBX2.13
Renishaw PLC5,175.00 GBX-0.86

About Author

Samuel Meakin  is a fund analyst for Morningstar